Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
Public ClinicalTrials.gov record NCT02812420. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy
Study identification
- NCT ID
- NCT02812420
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 54 participants
Conditions and interventions
Conditions
- Hydronephrosis
- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
- Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
- Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
- Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant
- Renal Pelvis Urothelial Carcinoma
- Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage II Renal Pelvis Cancer AJCC v7
- Stage II Ureter Cancer AJCC v7
- Stage II Urethral Cancer AJCC v7
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage III Renal Pelvis Cancer AJCC v7
- Stage III Ureter Cancer AJCC v7
- Stage III Urethral Cancer AJCC v7
- Stage IV Renal Pelvis Cancer AJCC v7
- Stage IV Ureter Cancer AJCC v7
- Stage IV Urethral Cancer AJCC v7
- Ureter Urothelial Carcinoma
- Urethral Urothelial Carcinoma
Interventions
- Durvalumab Biological
- Therapeutic Conventional Surgery Procedure
- Tremelimumab Biological
Biological · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2017
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Mar 4, 2026
2017 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02812420, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02812420 live on ClinicalTrials.gov.